The Week Ahead in Life Sciences

研报英文原文证据摘录

The Week Ahead in Life Sciences

$9,659 Late 2Q26 Topline data for Ph 3 ABTECT Maintenance study of obefazimod in UC

Denali Therapeutics DNLI Outperform $3,077 1H26 Top-line data from Phase 2 study of DNL758 in moderate to severe ulcerative colitis

Edgewise Therapeutics EWTX Outperform $3,659 1H26 Report Phase 1 SAD/MAD data of EDG-15400 in healthy adults

Pharvaris N.V. PHVS Outperform $2,139 1H26 Submit NDA for deucrictibant in on-demand treatment of HAE attacks

CG Oncology CGON Outperform $6,133 1H26 Topline data from PIVOT-006 investigating creto in IR-NMIBC

Black Diamond Therapeutics BDTX Outperform $164 1H26 Final Ph 2 data of silevertinib (BDTX-1535) in later line NSCLC w/ non-classical EGFRm

argenx SE ARGX Outperform $50,553 1H26 Topline data from ADAPT-JR (pediatric MG)

Cogent Biosciences COGT Outperform $5,842 1H26 Submit NDA for bezuclastinib in advSM

Hansa Biopharma HNSA Outperform $2,923 1H26 Complete enrollment of Ph 2 GNT-018-IDES trial of imlifidase in Crigler-Najjar Syndrome

Hansa Biopharma HNSA Outperform $2,923 1H26 Potential initiation of pivotal HNSA-5487 study in Guillain-Barre Syndrome

Beam Therapeutics BEAM Outperform $3,038 1H26 Complete HV dosing for BEAM-103 (CD117 mAb) component of ESCAPE

ORIC Pharmaceuticals ORIC Outperform $863 1H26 Start pivotal Ph 3 study of rinzimetostat (ORIC-944) in mCRPC

Prime Medicine PRME Outperform $565 1H26 File IND for PM577 in Wilson’s Disease

Corbus Pharmaceuticals CRBP Outperform $222 Summer 2026 Data from CANYON-1 invesitgating CRB-913 in obese patients

Sionna Therapeutics SION Outperform $1,931 Summer 2026 Potential Phase 2a PreciSION data -- SION-719 as add-on to Trikafta

Sionna Therapeutics SION Outperform $1,931 Summer 2026 Potential Phase 1 data for SION-451 in healthy volunteers -- select combo